

Mikko Airavaara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3365746/publications.pdf>

Version: 2024-02-01

80
papers

3,878
citations

117625

34
h-index

133252

59
g-index

83
all docs

83
docs citations

83
times ranked

5179
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurobiology of the incubation of drug craving. Trends in Neurosciences, 2011, 34, 411-420.	8.6	555
2	Development and plasticity of meningeal lymphatic vessels. Journal of Experimental Medicine, 2017, 214, 3645-3667.	8.5	311
3	Role of BDNF and GDNF in drug reward and relapse: A review. Neuroscience and Biobehavioral Reviews, 2010, 35, 157-171.	6.1	187
4	Effects of Neurotrophic Factors in Glial Cells in the Central Nervous System: Expression and Properties in Neurodegeneration and Injury. Frontiers in Physiology, 2019, 10, 486.	2.8	169
5	Mesencephalic astrocyte-derived neurotrophic factor reduces ischemic brain injury and promotes behavioral recovery in rats. Journal of Comparative Neurology, 2009, 515, 116-124.	1.6	132
6	Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) Secretion and Cell Surface Binding Are Modulated by KDEL Receptors. Journal of Biological Chemistry, 2013, 288, 4209-4225.	3.4	127
7	Viral vectors for neurotrophic factor delivery: A gene therapy approach for neurodegenerative diseases of the CNS. Pharmacological Research, 2010, 61, 14-26.	7.1	116
8	CDNF Protects the Nigrostriatal Dopamine System and Promotes Recovery after MPTP Treatment in Mice. Cell Transplantation, 2012, 21, 1213-1223.	2.5	112
9	Targeted Over-Expression of Glutamate Transporter 1 (GLT-1) Reduces Ischemic Brain Injury in a Rat Model of Stroke. PLoS ONE, 2011, 6, e22135.	2.5	94
10	Role of microglia in ischemic focal stroke and recovery: focus on Toll-like receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 79, 3-14.	4.8	90
11	Identification of Novel GDNF Isoforms and cis-Antisense GDNFOS Gene and Their Regulation in Human Middle Temporal Gyus of Alzheimer Disease*. Journal of Biological Chemistry, 2011, 286, 45093-45102.	3.4	86
12	Widespread cortical expression of MANF by AAV serotype 7: Localization and protection against ischemic brain injury. Experimental Neurology, 2010, 225, 104-113.	4.1	78
13	Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease. FEBS Letters, 2015, 589, 3739-3748.	2.8	71
14	MANF Promotes Differentiation and Migration of Neural Progenitor Cells with Potential Neural Regenerative Effects in Stroke. Molecular Therapy, 2018, 26, 238-255.	8.2	71
15	Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy. Human Gene Therapy, 2015, 26, 550-559.	2.7	67
16	Poststroke delivery of MANF promotes functional recovery in rats. Science Advances, 2018, 4, eaap8957.	10.3	64
17	Constitutive Ret Activity in Knock-In Multiple Endocrine Neoplasia Type B Mice Induces Profound Elevation of Brain Dopamine Concentration via Enhanced Synthesis and Increases the Number of TH-Positive Cells in the Substantia Nigra. Journal of Neuroscience, 2007, 27, 4799-4809.	3.6	63
18	Neuron-Specific Genome Modification in the Adult Rat Brain Using CRISPR-Cas9 Transgenic Rats. Neuron, 2019, 102, 105-119.e8.	8.1	62

#	ARTICLE	IF	CITATIONS
19	Increased extracellular dopamine concentrations and FosB/ΔFosB expression in striatal brain areas of heterozygous GDNF knockout mice. <i>European Journal of Neuroscience</i> , 2004, 20, 2336-2344.	2.6	53
20	Endogenous GDNF in ventral tegmental area and nucleus accumbens does not play a role in the incubation of heroin craving. <i>Addiction Biology</i> , 2011, 16, 261-272.	2.6	52
21	Local Administration of AAV-BDNF to Subventricular Zone Induces Functional Recovery in Stroke Rats. <i>PLoS ONE</i> , 2013, 8, e81750.	2.5	51
22	Role of two sequence motifs of mesencephalic astrocyte-derived neurotrophic factor in its survival-promoting activity. <i>Cell Death and Disease</i> , 2015, 6, e2032-e2032.	6.3	50
23	Update of neurotrophic factors in neurobiology of addiction and future directions. <i>Neurobiology of Disease</i> , 2017, 97, 189-200.	4.4	48
24	MANF Is Essential for Neurite Extension and Neuronal Migration in the Developing Cortex. <i>ENeuro</i> , 2017, 4, ENEURO.0214-17.2017.	1.9	48
25	Differentiation and molecular heterogeneity of inhibitory and excitatory neurons associated with midbrain dopaminergic nuclei. <i>Development (Cambridge)</i> , 2015, 143, 516-29.	2.5	46
26	Differential Spinal and Supraspinal Activation of Glia in a Rat Model of Morphine Tolerance. <i>Neuroscience</i> , 2018, 375, 10-24.	2.3	46
27	In heterozygous GDNF knockout mice the response of striatal dopaminergic system to acute morphine is altered. <i>Synapse</i> , 2006, 59, 321-329.	1.2	45
28	Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model. <i>Journal of Controlled Release</i> , 2016, 232, 113-119.	9.9	44
29	Chronic nicotine modifies the effects of morphine on extracellular striatal dopamine and ventral tegmental GABA. <i>Journal of Neurochemistry</i> , 2008, 107, 844-854.	3.9	43
30	AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models. <i>Genes</i> , 2017, 8, 63.	2.4	43
31	Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat. <i>Journal of Neuroscience Research</i> , 2016, 94, 318-328.	2.9	39
32	Transgenic animal models of neurodegeneration based on human genetic studies. <i>Journal of Neural Transmission</i> , 2011, 118, 27-45.	2.8	38
33	Neurorestoration. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S143-S146.	2.2	38
34	Implementation of deep neural networks to count dopamine neurons in substantia nigra. <i>European Journal of Neuroscience</i> , 2018, 48, 2354-2361.	2.6	38
35	Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease. <i>Neurobiology of Disease</i> , 2016, 96, 335-345.	4.4	36
36	Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models. <i>Current Protocols in Neuroscience</i> , 2020, 91, e88.	2.6	36

#	ARTICLE	IF	CITATIONS
37	Multifunctional Nanotube- <i>mu</i> coadhesive Poly(methyl vinyl ether- <i>co</i> -maleic) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Delivery. <i>Advanced Healthcare Materials</i> , 2017, 6, 1700629.	7.6	35
38	Post-stroke Intranasal (+)-Naloxone Delivery Reduces Microglial Activation and Improves Behavioral Recovery from Ischemic Injury. <i>ENeuro</i> , 2018, 5, ENEURO.0395-17.2018.	1.9	35
39	Cerebral dopamine neurotrophic factor deficiency leads to degeneration of enteric neurons and altered brain dopamine neuronal function in mice. <i>Neurobiology of Disease</i> , 2020, 134, 104696.	4.4	33
40	Intrastrially Infused Exogenous CDNF Is Endocytosed and Retrogradely Transported to Substantia Nigra. <i>ENeuro</i> , 2017, 4, ENEURO.0128-16.2017.	1.9	32
41	Short-term Preoperative Dietary Restriction Is Neuroprotective in a Rat Focal Stroke Model. <i>PLoS ONE</i> , 2014, 9, e93911.	2.5	29
42	Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease. <i>Neuroscience</i> , 2018, 374, 250-263.	2.3	27
43	<i>GDNF</i> / <i>RET</i> Signaling Pathway Activation Eliminates Lewy Body Pathology in Midbrain Dopamine Neurons. <i>Movement Disorders</i> , 2020, 35, 2279-2289.	3.9	27
44	Cerebral dopamine neurotrophic factor reduces α -synuclein aggregation and propagation and alleviates behavioral alterations in <i>AVivo</i> . <i>Molecular Therapy</i> , 2021, 29, 2821-2840.	8.2	26
45	MANF Ablation Causes Prolonged Activation of the UPR without Neurodegeneration in the Mouse Midbrain Dopamine System. <i>ENeuro</i> , 2020, 7, ENEURO.0477-19.2019.	1.9	26
46	Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease. <i>Journal of Neuroscience Research</i> , 2018, 97, 346-361.	2.9	24
47	Engineered antibody-functionalized porous silicon nanoparticles for therapeutic targeting of pro-survival pathway in endogenous neuroblasts after stroke. <i>Biomaterials</i> , 2020, 227, 119556.	11.4	23
48	Effects of repeated morphine on locomotion, place preference and dopamine in heterozygous glial cell line-derived neurotrophic factor knockout mice. <i>Genes, Brain and Behavior</i> , 2007, 6, 287-298.	2.2	22
49	Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse. <i>Experimental Brain Research</i> , 2017, 235, 2189-2202.	1.5	22
50	Pre- α -pro-GDNF and Pre- β -pro-GDNF Isoforms Are Neuroprotective in the 6-hydroxydopamine Rat Model of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 457.	2.4	21
51	Molecular profile of the rat peri-infarct region four days after stroke: Study with MANF. <i>Experimental Neurology</i> , 2020, 329, 113288.	4.1	18
52	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. <i>Cell Reports</i> , 2021, 35, 109040.	6.4	18
53	Neuroprotective and reparative effects of endoplasmic reticulum luminal proteins α -mesencephalic astrocyte-derived neurotrophic factor and cerebral dopamine neurotrophic factor. <i>Croatian Medical Journal</i> , 2019, 60, 99-109.	0.7	17
54	Characterization of the striatal dopaminergic neurotransmission in MEN2B mice with elevated cerebral tissue dopamine. <i>Journal of Neurochemistry</i> , 2008, 105, 1716-1725.	3.9	16

#	ARTICLE	IF	CITATIONS
55	Towards developing a model to study alcohol drinking and craving in female mice housed in automated cages. <i>Behavioural Brain Research</i> , 2018, 352, 116-124.	2.2	15
56	9-cis retinoic acid induces neurorepair in stroke brain. <i>Scientific Reports</i> , 2017, 7, 4512.	3.3	14
57	AAV-mediated targeting of gene expression to the peri-infarct region in rat cortical stroke model. <i>Journal of Neuroscience Methods</i> , 2014, 236, 107-113.	2.5	12
58	Secondary Pathology of the Thalamus after Focal Cortical Stroke in Rats is not Associated with Thermal or Mechanical Hypersensitivity and is Not Alleviated by Intra-Thalamic Post-Stroke Delivery of Recombinant CDFN or MANF. <i>Cell Transplantation</i> , 2019, 28, 425-438.	2.5	12
59	Accumbal μ -Opioid Receptors Modulate Ethanol Intake in Alcohol-Preferring Alko Alcohol Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 2114-2123.	2.4	11
60	Morphological Heterogeneity of the Endoplasmic Reticulum within Neurons and Its Implications in Neurodegeneration. <i>Cells</i> , 2021, 10, 970.	4.1	11
61	Studying Pre-formed Fibril Induced α -Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	11
62	LPR Responsive Genes Manf and Xbp1 in Stroke. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	3.7	10
63	Suppression of endogenous PPAR β increases vulnerability to methamphetamine-induced injury in mouse nigrostriatal dopaminergic pathway. <i>Psychopharmacology</i> , 2012, 221, 479-492.	3.1	9
64	Cerebral Dopamine Neurotrophic Factor Diffuses Around the Brainstem and Does Not Undergo Anterograde Transport After Injection to the Substantia Nigra. <i>Frontiers in Neuroscience</i> , 2019, 13, 590.	2.8	7
65	Domain-Independent Inhibition of CBP/p300 Attenuates α -Synuclein Aggregation. <i>ACS Chemical Neuroscience</i> , 2021, 12, 2273-2279.	3.5	7
66	The μ -opioid receptor antagonist JD1c decreases ethanol intake in alcohol-preferring AA rats. <i>Psychopharmacology</i> , 2018, 235, 1581-1591.	3.1	6
67	Neuronal Activation Stimulates Cytomegalovirus Promoter-Driven Transgene Expression. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 14, 180-188.	4.1	6
68	Mitoxantrone, pixantrone and mitoxantrone (2-hydroxyethyl)piperazine are toll-like receptor 4 antagonists, inhibit NF- κ B activation, and decrease TNF-alpha secretion in primary microglia. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 154, 105493.	4.0	6
69	A novel variant in SMG9 causes intellectual disability, confirming a role for nonsense-mediated decay components in neurocognitive development. <i>European Journal of Human Genetics</i> , 2022, 30, 619-627.	2.8	6
70	Nanoscale geometry determines mechanical biocompatibility of vertically aligned nanofibers. <i>Acta Biomaterialia</i> , 2022, 146, 235-247.	8.3	6
71	Modulating Microglia/Macrophage Activation by CDFN Promotes Transplantation of Fetal Ventral Mesencephalic Graft Survival and Function in a Hemiparkinsonian Rat Model. <i>Biomedicines</i> , 2022, 10, 1446.	3.2	6
72	Hesperine, a new imidazole alkaloid and α -synuclein binding activity of 1-methyl-1,2,7,8-tetrahydro-2,8-dioxoadenosine from the marine sponge <i>Clathria</i> (Thalysias) cf. hesperia. <i>Results in Chemistry</i> , 2022, 4, 100302.	2.0	4

#	ARTICLE	IF	CITATIONS
73	Î±-Synuclein binding activity of the plant growth promoter asterubine. Bioorganic and Medicinal Chemistry Letters, 2022, 64, 128677.	2.2	4
74	Synthesis of 7Î²-hydroxy-8-ketone opioid derivatives with antagonist activity at mu- and delta-opioid receptors. European Journal of Medicinal Chemistry, 2018, 151, 495-507.	5.5	3
75	The overexpression of GDNF in nucleus accumbens suppresses alcohol-seeking behavior in group-housed C57Bl/6J female mice. Journal of Biomedical Science, 2021, 28, 87.	7.0	3
76	Cell Culture Media, Unlike the Presence of Insulin, Affect Î±-Synuclein Aggregation in Dopaminergic Neurons. Biomolecules, 2022, 12, 563.	4.0	3
77	Female C57BL/6J Mice Show Alcohol-Seeking Behaviour after Withdrawal from Prolonged Alcohol Consumption in the Social Environment. Alcohol and Alcoholism, 2022, 57, 405-412.	1.6	2
78	P2.002 Intranigral injection of CDNF promotes functional recovery of nigrostriatal dopaminergic circuit in a lesion model of Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S88-S89.	2.2	1
79	Gene delivery for Parkinson's disease. , 2020, , 597-625.		0
80	Intranasal delivery of recombinant MANF protein is neuroprotective in cortical ischemia-reperfusion injury in rats. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-1-36.	0.0	0